ArticleAmerican journal of nuclear medicine and molecular imaging2012
Molecular imaging of insulin-like growth factor 1 receptor in cancer.
Article in American journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- In vivo evaluation of IGF1R/IR PET ligand [Bioorganic & medicinal chemistry letters · 2017Article
- ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.Molecular pharmaceutics · 2016Article
- Article
- Generation and screening of monoclonal antibodies for immunoPET imaging of IGF1R in prostate cancer.Molecular pharmaceutics · 2014Article
- Antibody-based imaging of HER-2: moving into the clinic.Current molecular medicine · 2013Review
- Functionalized upconversion nanoparticles: versatile nanoplatforms for translational research.Current molecular medicine · 2013Review
- Quantum dot-based nanoprobes for in vivo targeted imaging.Current molecular medicine · 2013Review
- Positron emission tomography imaging of atherosclerosis.Theranostics · 2013Review
- Synthesis and in vitro evaluation of [18F]BMS-754807: a potential PET ligand for IGF-1R.Bioorganic & medicinal chemistry letters · 2013Article
- ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW.American journal of translational research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Insulin-like growth factor 1 receptor (IGF1R) plays an important role in proliferation, apoptosis, angiogenesis, and tumor invasion. Histology and in situ hybridization studies have revealed that IGF1R was significantly up-regulated at the protein and mRNA level in many types of cancer. Since measuring IGF1R expression with immunohistochemistry has many limitations, non-invasive imaging of IGF1R can allow for more accurate patient stratification (e.g. selecting the right patient population for IGF1R-targeted therapy) and more effective monitoring of the therapeutic responses in cancer patients. In this review, we will summarize the current status of imaging IGF1R expression in cancer, which includes single-photon emission computed tomography, positron emission tomography, fluorescence, and γ-camera imaging. The four major classes of ligands that have been developed for non-invasive visualization of IGF1R will be discussed: proteins, antibodies, peptides, and affibodies. To date, molecular imaging of IGF1R expression is understudied and more research effort is needed in the future.
Identifiers
23066521PMC3477732W138186425What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.